1. Home
  2. EMF vs MOLN Comparison

EMF vs MOLN Comparison

Compare EMF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$16.94

Market Cap

311.7M

Sector

Finance

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$4.05

Market Cap

158.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMF
MOLN
Founded
1987
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
311.7M
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EMF
MOLN
Price
$16.94
$4.05
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
70.9K
3.6K
Earning Date
01-01-0001
03-12-2026
Dividend Yield
6.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$318.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.14
$3.36
52 Week High
$21.20
$5.36

Technical Indicators

Market Signals
Indicator
EMF
MOLN
Relative Strength Index (RSI) 31.35 34.20
Support Level $16.13 $4.04
Resistance Level $17.03 $4.07
Average True Range (ATR) 0.50 0.27
MACD -0.15 -0.07
Stochastic Oscillator 4.19 0.00

Price Performance

Historical Comparison
EMF
MOLN

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: